4.4 Review

Asthma in the elderly: what we know and what we have yet to know

Journal

WORLD ALLERGY ORGANIZATION JOURNAL
Volume 7, Issue -, Pages -

Publisher

ELSEVIER
DOI: 10.1186/1939-4551-7-8

Keywords

-

Funding

  1. AstraZeneca
  2. GlaxoSmithKline
  3. Merck Frosst
  4. Schering
  5. Altair
  6. Amgen
  7. Asmacure
  8. Boehringer-Ingleheim
  9. Genentech
  10. Novartis
  11. Ono Pharma
  12. Pharmaxis
  13. Wyeth
  14. Boehringer-Inglemeim
  15. Actelion
  16. Almirall
  17. Chiesi Farmaceutici
  18. Elevation Pharmaceuticals
  19. Euromediform
  20. Merck Sharp Dohme
  21. Nycomed
  22. OM Pharma
  23. Ferrer Group
  24. Pearl Therapeutics
  25. Roche
  26. Sigma-Tau Fondazione FADOI - Forest Research Institute
  27. Euromediform SrL
  28. German Centre for Lung Research
  29. Deutsches Zentrum fur Luft und Raumfahrt - German AerospaceCenter
  30. Menarini
  31. Mundipharma International
  32. Takeda
  33. TEVA Pharmaceuticals
  34. Pfizer
  35. Sigma-Tau
  36. Boehringer Ingelheim
  37. Italian Ministry of Health
  38. Italian Ministry for University and Research

Ask authors/readers for more resources

In the past, asthma was considered mainly as a childhood disease. However, asthma is an important cause of morbidity and mortality in the elderly nowadays. In addition, the burden of asthma is more significant in the elderly than in their younger counterparts, particularly with regard to mortality, hospitalization, medical costs or health-related quality of life. Nevertheless, asthma in the elderly is still been underdiagnosed and undertreated. Therefore, it is an imperative task to recognize our current challenges and to set future directions. This project aims to review the current literature and identify unmet needs in the fields of research and practice for asthma in the elderly. This will enable us to find new research directions, propose new therapeutic strategies, and ultimately improve outcomes for elderly people with asthma. There are data to suggest that asthma in older adults is phenotypically different from young patients, with potential impact on the diagnosis, assessment and management in this population. The diagnosis of AIE in older populations relies on the same clinical findings and diagnostic tests used in younger populations, but the interpretation of the clinical data is more difficult. The challenge today is to encourage new research in AIE but to use the existing knowledge we have to make the diagnosis of AIE, educate the patient, develop a therapeutic approach to control the disease, and ultimately provide a better quality of life to our elderly patients.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available